Metabolomic Signatures in Doxorubicin-Induced Metabolites Characterization, Metabolic Inhibition, and Signaling Pathway Mechanisms in Colon Cancer HCT116 Cells

Doxorubicin (DOX) is a chemotherapeutic agent is used for various cancer cells. To characterize the chemical structural components and metabolic inhibition, we applied a DOX to HCT116 colon cancer cells using an independent metabolites profiling approach. Chemical metabolomics has been involved in t...

Full description

Saved in:
Bibliographic Details
Published in:Metabolites 2022-10, Vol.12 (11), p.1047
Main Authors: Ganesan, Raja, Prabhakaran, Vasantha-Srinivasan, Valsala Gopalakrishnan, Abilash
Format: Article
Language:English
Subjects:
Acetic acid
Alanine
Analysis
Cancer
Cell division
Colon cancer
Colorectal cancer
Cytotoxicity
Development and progression
Discriminant analysis
Doxorubicin
Drug delivery
Drug metabolism
Drug therapy
Glutamine
HCT116 cells
Health aspects
Isoleucine
Lysine
metabolic profiling
Metabolism
Metabolites
Metabolomics
Methionine
NMR
Nuclear magnetic resonance
Oncology, Experimental
Phenylalanine
Phosphocholine
Physiological aspects
Signal transduction
Software
Spectroscopy
Spectrum analysis
Taurine
Valine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Doxorubicin (DOX) is a chemotherapeutic agent is used for various cancer cells. To characterize the chemical structural components and metabolic inhibition, we applied a DOX to HCT116 colon cancer cells using an independent metabolites profiling approach. Chemical metabolomics has been involved in the new drug delivery systems. Metabolomics profiling of DOX-applied HCT116 colon cancer cellular metabolisms is rare. We used 1H nuclear magnetic resonance (NMR) spectroscopy in this study to clarify how DOX exposure affected HCT116 colon cancer cells. Metabolomics profiling in HCT116 cells detects 50 metabolites. Tracking metabolites can reveal pathway activities. HCT116 colon cancer cells were evenly treated with different concentrations of DOX for 24 h. The endogenous metabolites were identified by comparison with healthy cells. We found that acetate, glucose, glutamate, glutamine, sn-glycero-3-phosphocholine, valine, methionine, and isoleucine were increased. Metabolic expression of alanine, choline, fumarate, taurine, o-phosphocholine, inosine, lysine, and phenylalanine was decreased in HCT116 cancer cells. The metabolic phenotypic expression is markedly altered during a high dose of DOX. It is the first time that there is a metabolite pool and phenotypic expression in colon cancer cells. Targeting the DOX-metabolite axis may be a novel strategy for improving the curative effect of DOX-based therapy for colon cancer cells. These methods facilitate the routine metabolomic analysis of cancer cells.
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo12111047